Cognitive Impairments in Hashimoto’s Encephalopathy: A Case-Control Study

Jianhong Wang1, Jun Zhang2, Lan Xu1, Yunbo Shi1, Xunyi Wu1, Qihao Guo1
1 Department of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Shanghai Medical College, Fudan University, Shanghai, China, 2 Department of Radiology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

Abstract

Background/Aims: Hashimoto’s encephalopathy is considered as a treatable dementia, but it is often misdiagnosed. We investigated cognitive impairment and the MRI pathology of Hashimoto’s encephalopathy patients.

Methods: The study comprised eight patients with Hashimoto’s encephalopathy, 16 patients with mild Alzheimer’s disease and 24 healthy subjects. A neuropsychological battery included assessments of memory, language, attention, executive function and visuospatial ability. Cranial MRI was obtained from all Hashimoto’s encephalopathy patients.

Results: Hashimoto’s encephalopathy and mild Alzheimer’s disease showed cognitive impairments in episodic memory, attention, executive function and visuospatial ability, but naming ability was unaffected in Hashimoto’s encephalopathy. The MRI of Hashimoto’s encephalopathy showed leukoencephalopathy-like type or limbic encephalitis-like type; the lesions did not affect the temporal cortex which plays a role in naming ability.

Conclusion: Except that the naming ability was retained, the impairments in cognitive functions for the Hashimoto’s encephalopathy patients were similar to those of Alzheimer’s disease patients. These results were consistent with the MRI findings.

Introduction

Hashimoto’s encephalopathy (HE) is a rare, controversial neurological disorder associated with high titers of antithyroid antibodies [1,2]. Patients are mostly women [2]. Typically, HE is a steroid-responsive, relapsing–remitting and progressive encephalopathy. The clinical manifestations of HE are various, but frequently involve disorders of consciousness (e.g., confusion, coma), stroke-like episodes, cognitive decline, seizures (including focal or generalized seizures), psychiatric manifestations (such as depression, mania or hallucinations), myoclonus and movement disorders [3–5]. Although cognitive impairment is commonly described in cases of HE, the exact nature of the impairment and the associated neuroimaging pathology remain unclear.

An investigation of the cognitive symptoms and homologous neuroimaging manifestations of HE will contribute to the differential diagnosis of dementia. Furthermore, as the diagnosis criteria of HE is controversial, such research would help to confirm the diagnosis of HE, and contribute to the assessment of responses to treatment [6]. This study aims to analyze the cognitive impairment characteristics of HE by comparing HE patients with early-onset Alzheimer’s disease (AD) patients and a normal control group. In addition, the magnetic resonance imaging (MRI) data of HE patients is retrospectively analyzed to investigate the pathological status of HE.

Materials and Methods

Participants

Participants included 8 patients with HE and 16 patients with mild AD, who were recruited from the Memory Clinic, Department of Neurology, Huashan Hospital, from January 2010 to March 2012.

The HE patients (the case group) were carefully selected according to the following criteria: 1) clinical manifestations of HE in accordance with generally accepted diagnostic criteria [2,7]: cognitive impairment (Clinical Dementia Rating, CDR = 1) with or without neuropsychological symptoms; seizures; focal neurological deficits or movement disorders; 2) elevated titers of antithyroid antibodies in serum, including antithyroid peroxidase antibodies (anti-TPO; normal <60 IU/ml) and antithyroglobulin antibodies (anti-TG; normal <60 IU/ml); 3) negative results for infectious diseases (determined using the Treponema pallidum particle agglutination test and rapid plasma regain test, anti-HIV antibody, anti-rubella IgG, IgM, anti-measles IgM, anti-cytomegalovirus IgG, IgM), tumor antigens (CEA, AFP, CA199, CA125, CA125,
NESE, SCC et al), para-neoplastic antibodies (immunoblot anti-Hu neuronal nuclear antibody IgG, immunoblot anti-Yo neuronal nuclear antibody IgG, immunoblot anti-Ri neuronal nuclear antibody IgG, immunoblot anti-CV2 neuronal nuclear antibody IgG et al), and other immune antibodies including ANA, ENA, ANCA, dsDNA, as well as serum voltage gated potassium channel (VGKC) antibodies and anti-NMDA receptor antibodies; 4) cognitive assessment was performed prior to steroid treatment; 5) to achieve the neuropsychological tests, we excluded the patients with disorders of consciousness, visual or auditory deficits, or obvious symptoms of medical or psychiatric dysfunction (including mania and depression) within the previous month; 6) EEG showed no triphasic wave.

The mild AD patients (patient control group) met the following criteria [8]: 1) diagnosis of AD according to the DSM-IV [9], (CDR = 1); 2) to achieve the neuropsychological tests, we excluded the patients with disorders of consciousness, obvious medical diseases, psychiatric/psychological dysfunction (including anxiety, mania and depression) within the previous month or visual or auditory deficits.

Twenty-four healthy old subjects from urban communities in Shanghai were chosen as the normal control group using cluster sampling. All participants were native Chinese speakers. There were no statistical differences among the three groups in terms of sex or educational level (P>0.05; Table 1). Informed written consent was obtained directly from patients or family members. The ethics committee at Huashan Hospital, Fudan University approved the protocol.

**Neuropsychological Assessment**

Participants were given neuropsychological tests by a trained rater who was unaware of the study aims or the patient diagnosis. A comprehensive neuropsychological battery was used, which included assessments of memory, language, attention, executive function and visuospatial ability. All tests have been shown to have good reliability and validity when used in Chinese populations [10]. The specific tests employed were: the Center for Epidemiologic Studies Depression Scale [11]; the Auditory Verbal Learning Test (AVLT) [12,13]; the Rey-Osterrieth Complex Figure Test (CFT) [13], the event-based prospective memory test (EBPM) and the time-based prospective memory test (TBPM) [14,15]; the Boston Naming Test (BNT, 30-item version) [16]; the verbal fluency test (VFT) [17–19]; the Trail Making Test, parts A and B (TMT-A, TMT-B) [20]; the Symbol Digit Modalities Test (SDMT) [21]; the Stroop Color-Word Test (SCWT) [22]; the similarity test [23]; the stick test [24]; and the clock drawing test (CDT) [25,26]. (Please refer to Dementia and Geriatric Cognitive Disorders, 2011; 31:284–290 for details).

**MRI Examination**

All MR images were obtained using a 3.0-T system (Signa VH/i, GE Healthcare, Milwaukee, WI, USA) equipped with a standard head coil. The subject’s head was immobilized in the head coil with foam padding. The conventional MRI sequences included axial T1-weighted imaging (T1WI), T2-weighted imaging (T2WI) and fluid-attenuated inversion recovery (FLAIR). Coronal images were used because the hippocampus is more easily identified in this acquisition plane.

**Statistical Analysis**

The ages of subjects were significantly different between the three groups. Therefore, the overall differences between the three groups were assessed using ANCOVA to remove the effect of age. Post-hoc pair-wise comparisons between the groups were made using the least significant differences test. The level of significance (p) was set at 0.05.

**Results**

The average age of the HE group was 38.88±11.57 years (3 males, 5 females; Table 1). The educational levels included elementary school (n = 1), junior high school (n = 2), senior high school (n = 3) and college (n = 2). Clinical examination revealed that symptoms/signs of HE included seizures (n = 4), psychological or psychiatric disorders (n = 5), stroke-like episodes (n = 2) and corticospinal abnormalities (n = 1). The clinical features of the HE cases are summarized in Table 2.

The tests for antithyroid antibodies (conducted to satisfy the diagnostic criteria) revealed that anti-TPO levels were greater than 1,300 IU/ml in five HE patients; the other three patients had anti-TPO levels greater than 400 IU/ml (i.e., 1253.63 IU/ml, 1113.2 IU/ml and 495.3 IU/ml). Anti-TG levels were greater than 90 IU/ml in all eight cases. Three of the patients were hyperthyroid.

Cerebral MRI showed that manifestations of HE varied from white matter alterations to hippocampus swelling to medial temporal lobe/hippocampus lesions (Figure 1A, B, Figure 2A, B).

The means ± SD of the neuropsychological test scores are summarized in Table 3. As expected, HE patients had greater cognitive impairment than the control subjects in most tests (p<0.05) except EBPM (2, non-language response), TBPM (2), BNT, VFT (fruit), stick test (copy) and CDT. Apart from BNT, there were no significant differences between mild AD and HE patients.

### Table 1. General information for the three groups (means ±SD).

| Index              | HE group (n = 8) | Normal group (n = 24) | mild AD group (n = 16) | F(2) value | P value |
|--------------------|-----------------|-----------------------|------------------------|------------|--------|
| Age                | 38.88±11.57     | 60.25±6.64*           | 60.44±5.76             | 28.204     | <0.001 |
| Years of Education | 12.50±2.45      | 13.38±2.39            | 11.38±3.20             | 2.642      | 0.082  |
| Gender(M/F)        | 5/3             | 5/11                  | 15/9                   | 4.087      | 0.130  |
| MMSE Total score   | 21.63±1.51      | 28.75±1.19*           | 23.31±2.94             | 56.586     | <0.001 |
| CESD               | 7.58±3.47       | 9.16±7.99             | 9.00±5.07              | 0.197      | 0.898  |

CES-D = Center for Epidemiologic Studies Depression Scale.

* a = 2 analysis.

** = p<0.01, normal group vs. HE group.

[10.1371/journal.pone.0055758.t001]
Since the first description of Hashimoto’s encephalopathy (HE) by Brain et al. [27] in 1966, around a hundred cases have been reported worldwide. Most of the published case reports comprise a small sample, and there is no comprehensive statistical analysis of the clinical features associated with HE. In fact, HE remains problematic in terms of its pathophysiology, diagnosis and treatment. The diagnostic criteria proposed by Peschen-Rosin et al. in 1999 [28] encompassed seizures, psychiatric disorders and focal neurological deficits, with elevated thyroid antibodies and an excellent response to steroids. However, this classification of HE underestimates the significance of memory loss and the pathological differences observed in MRI, and overestimates the response to steroids. More and more studies are showing that cognitive impairment is one of the main manifestations of HE, but this aspect has been overlooked due to the multiple and protracted neuropsychological manifestations associated with this condition [27–29]. In addition, only 50% of patients with HE are responsive to corticosteroids [29].

The current diagnostic criteria confirm that Hashimoto’s encephalopathy is a diagnosis of exclusion [30]. In the current study, patients were diagnosed with HE on the basis of typical clinical manifestations and a high titer of antithyroid antibodies.

**Table 2. Clinical and laboratory findings for the HE group.**

| Case | Age (yrs) | Sex | Clinical presentation | Special examinations | Treatment | Evolution |
|------|-----------|-----|-----------------------|----------------------|-----------|-----------|
| 1    | 58        | F   | Partial complex seizures, cognitive impairment | Hippocampus swelling and N angio, EEG diffuse slowing, sharp waves<left | A, S | Occasional relapses, then stable |
| 2    | 47        | F   | Partial complex and generalized seizures, cognitive impairment | MRI bilateral medial temporal and hippocampus FLAIR hypersignal, EEG diffuse slowing, sharp waves<right | A, S | Improvement after ttt |
| 3    | 41        | F   | Cognitive impairment, apathy | MRI white matter alterations, N EEG | S | Improvement after ttt, persistent mild cognitive impairment |
| 4    | 24        | F   | Focal and generalized seizures, cognitive impairment | MRI left medial temporal and amygdala FLAIR hypersignal, N EEG | A,S | Improvement after ttt, seizure free |
| 5    | 38        | M   | Cognitive impairment, anxiety | Hippocampus mild swelling, EEG delta slowing | S,T4 | Slight improvement after ttt |
| 6    | 46        | M   | Generalized seizures, cognitive impairment | Hippocampus mild swelling, EEG slowing | S | Improvement after ttt, no seizure relapse |
| 7    | 31        | F   | Cognitive impairment, occasional stupor | MRI white matter alteration, EEG diffuse slowing | S | Significant improvement after ttt, relapses |
| 8    | 26        | M   | Cognitive impairment | Hippocampus well-stacked, N EEG | S | Improvement after ttt |

N, normal; angio, cerebral angiography; CT, computed tomography; EEG, electroencephalogram; MRI, magnetic resonance imaging; S, steroid; A, anticonvulsant; t, treatment; T4, levothyroxin.

doi:10.1371/journal.pone.0055758.t002

**Discussion**

Since the first description of Hashimoto’s encephalopathy (HE) by Brain et al. [27] in 1966, around a hundred cases have been reported worldwide. Most of the published case reports comprise a small sample, and there is no comprehensive statistical analysis of the clinical features associated with HE. In fact, HE remains problematic in terms of its pathophysiology, diagnosis and treatment. The diagnostic criteria proposed by Peschen-Rosin et al. in 1999 [28] encompassed seizures, psychiatric disorders and focal neurological deficits, with elevated thyroid antibodies and an excellent response to steroids. However, this classification of HE underestimates the significance of memory loss and the pathological differences observed in MRI, and overestimates the response to steroids. More and more studies are showing that cognitive impairment is one of the main manifestations of HE, but this aspect has been overlooked due to the multiple and protracted neuropsychological manifestations associated with this condition [27–29]. In addition, only 50% of patients with HE are responsive to corticosteroids [29].

The current diagnostic criteria confirm that Hashimoto’s encephalopathy is a diagnosis of exclusion [30]. In the current study, patients were diagnosed with HE on the basis of typical clinical manifestations and a high titer of antithyroid antibodies.

**Figure 1. Leukoencephalopathy-like manifestations on MRI images.** (A, B) Axial MRI images demonstrate widespread periventricular hyperintense signals in the cerebral white matter.

doi:10.1371/journal.pone.0055758.g001
encephalitis were para-neoplastic disease, since our patients have no teratomas. All our patients had negative anti-TPO levels greater than 400 IU/ml, Anti-TG levels greater than 1,300 IU/ml in five HE patients; the other three cases had elevated titers of antithyroid antibodies (anti-TPO levels were greater than 90 IU/ml in all eight cases), thus we might finally got the negative results. Otherwise, we carried out the inspection of anti-NMDA receptor antibody and voltage gated potassium channel (VGKC) antibody. A serum screening for these two antibodies was routinely done for differential diagnosis of anti-NMDAR encephalitis and limbic encephalitis, which showed the similar manifestations as HE therefore easily confused with the HE disease. Many anti-NMDAR encephalitis cases were also typically women combined with sudden vasculitic type presented stroke-like episodes or a progressive subacute type associated with cognitive dysfunction, and other causes. We have detected most infectious and immune antibodies (especially anti-TPO) in serum, and after the exclusion of other causes. We have carried out the inspection of anti-NMDA receptor antibody and voltage gated potassium channel (VGKC) antibody. A serum screening for these two antibodies was routinely done for differential diagnosis of anti-NMDAR encephalitis and limbic encephalitis, which showed the similar manifestations as HE therefore easily confused with the HE disease. Many anti-NMDAR encephalitis cases were also typically women combined with ovarian teratomas. Our female ones have done routine imaging exam, and found no teratomas. All our patients had negative anti-NMDA receptor antibody and showed better prognosis. We might exclude the anti-NMDAR encephalitis from both clinical manifestation and laboratory examination. Besides, most limbic encephalitis were para-neoplastic disease, since our patients have negative tumor antigens and neuronal nuclear antibodies screening (including anti-Hu IgG, anti-Yo IgG, anti-Ri IgG, anti-CV2 IgG et al), and negative serum VGKC antibody as well as the elevated titers of antithyroid antibodies (anti-TPO levels were greater than 1,300 IU/ml in five HE patients; the other three patients had anti-TPO levels greater than 400 IU/ml, Anti-TG levels were greater than 90 IU/ml in all eight cases), thus we might not first consider the diagnosis of the limbic encephalitis. It is reported that the disease may present in two clinical types, a sudden vasculitic type presented stroke-like episodes or a progressive subacute type associated with cognitive dysfunction, confusion and memory loss [30]. Our study focused on cognitive impairments of the second type; the vasculitic type of HE was scarcely included. Some reports have suggested that there are elevated CSF protein levels in HE. Lumbar punctures were not performed in this study, but future studies should consider including this for laboratory diagnosis.

As there is no gold-standard diagnostic test for HE, neuropsychological tests are an important tool that can help to confirm diagnosis and assess the response to corticosteroid treatment [6].

**Table 3.** Comparison of neuropsychological tests among the three groups (mean±SD).

| Index                     | HE group (n = 8) | NC group (n = 24) | mild AD group (n = 16) | F value | P value |
|---------------------------|-----------------|-------------------|------------------------|---------|---------|
| AVL1R                     | 1.88±1.36       | 4.67±1.31a        | 2.06±1.39              | 22.097  | <0.001  |
| AVL2R                     | 2.88±1.55       | 5.29±1.40b        | 3.50±1.21              | 9.874   | <0.001  |
| AVL3R                     | 3.38±2.13       | 6.88±1.80a        | 3.75±1.13              | 19.572  | <0.001  |
| AVL4R-short delay recall  | 1.25±1.75       | 5.42±1.53a        | 0.50±0.82              | 74.039  | <0.001  |
| AVL5R-long delay recall   | 0.63±0.92       | 5.25±1.36a        | 0.19±0.54              | 112.140 | <0.001  |
| AVL6R-cue recall          | 0.38±0.74       | 5.00±1.50a        | 0.31±0.70              | 84.918  | <0.001  |
| AVL7R-recognition         | 13.63±2.56      | 21.71±1.46a       | 13.75±3.00             | 77.264  | <0.001  |
| CFT-delay recall          | 2.75±2.12       | 14.88±6.48a       | 3.25±3.72              | 33.947  | <0.001  |
| EBPM-VR                   | 0.38±0.74       | 3.42±2.60b        | 0.25±0.58              | 14.271  | <0.001  |
| EBPM-NVR                  | 2.25±1.67       | 3.83±0.48         | 2.50±1.39              | 6.726   | 0.003   |
| TBPM-VR                   | 0.13±0.35       | 3.96±2.53a        | 0.31±0.60              | 21.290  | <0.001  |
| TBPM- NVR                 | 0.50±0.54       | 2.29±2.01         | 0.25±0.58              | 9.565   | <0.001  |
| SDMT-accidental memory    | 0.75±1.17       | 3.79±2.80a        | 0.75±1.07              | 12.716  | <0.001  |
| BNT (30 item)             | 19.38±4.17      | 22.08±3.40        | 20.25±4.30             | 1.252   | 0.296   |
| VFT-Animal                | 10.88±2.70      | 16.13±3.78b       | 11.00±3.27             | 11.841  | <0.001  |
| VFT-Fruit                 | 7.88±2.53       | 11.08±2.36        | 7.06±1.73              | 16.211  | <0.001  |
| VFT-Vegetable             | 8.38±2.20       | 11.92±2.87b       | 8.06±2.44              | 11.286  | <0.001  |
| TMT-A(s)                  | 76.13±19.03     | 51.75±20.18a      | 66.88±22.98            | 5.354   | <0.001  |
| SDMT                       | 31.88±12.92     | 48.63±9.38 b      | 32.94±10.33            | 12.000  | <0.001  |
| TMT-B(s)                  | 221.88±64.00    | 151.00±63.75b     | 225.25±93.80           | 5.687   | 0.006   |
| SCWT-C-time(s)            | 134.00±48.72    | 82.08±25.84b      | 119.13±34.61           | 7.467   | 0.002   |
| SCWT-C-right              | 32.13±8.88      | 44.38±3.66a       | 34.81±9.38             | 11.282  | <0.001  |
| Similarity test           | 7.75±1.98       | 14.00±4.52a       | 9.00±3.08              | 11.009  | <0.001  |
| CFT-copy                  | 26.63±7.60      | 34.38±7.26a       | 26.50±8.33             | 9.012   | 0.001   |
| Stick Test -copy          | 9.00±1.07       | 9.88±0.45         | 9.31±0.95              | 3.102   | 0.055   |
| Stick Test - rotate       | 2.00±0.76       | 5.33±2.68b        | 2.06±2.52              | 10.048  | <0.001  |
| CDT (Sunderland method)   | 6.00±1.93       | 7.79±1.25         | 6.75±1.34              | 3.457   | 0.040   |

a = P<0.01 HE vs. normal group; b = P<0.05 HE vs. normal group; AVL1T, Auditory Verbal Learning Test; CFT, Rey-Osterrieth Complex Figure Test; EBPM-VR, event-based prospective memory-verbal response; EBPM-NVR, event-based prospective memory-nonverbal response; TBPM-VR, time-based prospective memory-verbal response; TBPM-NVR, time-based prospective memory-verbal response-nonverbal response; SDMT, Symbol Digit Modalities Test; TMT, Trail Making Test; SCWT, Stroop Color-Word Test; CDT, clock drawing test. doi:10.1371/journal.pone.0057578.t003
We carried out a review of international papers that investigated cognitive impairment in HE; the research linking them was limited. Most of the relevant literature concerned case reports, using only Mini-Mental State Examination Scores (MMSE) for a rough assessment [31,32]. There are few case reports that entail a comprehensive examination of cognitive impairment patterns to estimate the steroid response. Cummings [33] reports that pre-treatment testing revealed global cognitive impairment, with deficits in: overall mental status; simple and complex attention; nonverbal reasoning; line orientation; and list, story and figure learning and recall. In addition, Mazzu [34] and Fukunaga [35] showed a diffuse pattern of cognitive impairment that eventually progressed toward a selective deficit in executive functions and procedural memory. They also suggested that this pattern of cognitive impairment, characterized by widespread brain involvement, primarily implicated the frontal lobe [34,35].

To investigate the cognitive impairment pattern of HE in a systematic manner, we recruited HE patients with mild, pre-treatment cognitive impairment, and compared the results with mild AD patients, and normal elders. To the best of our knowledge, it is the first statistical analysis of cognitive impairment associated with Hashimoto’s encephalopathy. The results showed that the scores for the HE group were worse than those of the normal control group in most tests. However, there was no difference between these two groups in terms of BNT. This suggested that there was an overall impairment in cognitive function for the HE patients, but long-term semantic memory (naming ability) remained unaffected. This pattern of cognitive impairment was associated with diffuse brain involvement, but rarely implicated the temporal cortex. However, when comparisons were made between the HE group and the mild AD group (who were matched for education, gender and MMSE scores), there was no significant difference in performance, indicating that HE might show a similar pattern of cognitive impairment to AD.

The patients’ cognitive function improved to some extent during or after steroid treatment; MMSE scores were elevated to 28–30/30. This is consistent with the generally accepted viewpoint that treatment with steroids promotes marked clinical improvement and usually infers a good prognosis [27–30,34,35]. This is of considerable importance for patients with rare but treatable causes of encephalopathy presenting with acute or subacute cognitive decline. Unfortunately, a comprehensive follow-up neuropsychological battery was not carried out. Further studies are needed to verify the detailed pattern of improvement following treatment.

MRI is widely used as a non-invasive means of studying pathological changes in the CNS, and it can provide a unique insight into the pathological status of HE. Among the eight cases of HE in this study, the MRI revealed two types of manifestation associated with HE: the more frequently reported leukoencephalopathy-like type, and limbic encephalitis-like type. Two of the patients (cases 3 and 7) showed the former manifestation-type, with widespread periventricular hyperintense signals in the cerebral white matter (Figure 1(A, B)). Similar pathologies were reported in two other case reports. One was a 65-year-old woman with subacute deterioration of cognitive function, whose brain MRI revealed diffuse high intensity in the white matter on diffusion and T2-weighted images, which mimicked leukoencephalopathy [36]. The other was a 50-year-old man presenting with lower motor neuron symptoms that had evolved over three years, and changes in behavior associated with attentive and cognitive impairment. This patient’s cranial MRI also revealed multiple subcortical white matter lesions [37].

In the current study, limbic encephalitis pathology was observed in cases 2 and 4. The foci of hypersignal on FLAIR for these patients were the bilateral/unilateral medial temporal and hippocampus hyperintense areas [38]. Lesions in the neighboring structures of the limbic lobe have occasionally been reported, such as localized symmetrical lesions in the bilateral pallidum to the genu of the internal capsule [35]. The remaining four cases in this study showed mild or severe hippocampus swelling but no signal

Figure 2. Limbic encephalitis-like manifestations on MRI images. (A) Coronal MRI image shows bilateral medial temporal and hippocampus hypersignal on FLAIR. (B) Axial MRI image shows left medial temporal and amygdala hypersignal on FLAIR. doi:10.1371/journal.pone.0055758.g002
intensity. On the basis of the neurological/psychiatric impairment, we believe that there should be a lesion present in these cases, which may be discovered using functional MRI (fMRI), e.g., blood oxygen level dependent (BOLD) fMRI, or DTI (diffusion tensor imaging). On the whole, the pathology revealed by MRI showed which may be discovered using functional MRI (fMRI), e.g., blood oxygen level dependent (BOLD) fMRI, or DTI (diffusion tensor imaging). However, it should be noted that the information provided by this article only showed the observed phenomena at a specific time point rather than over a period of time. We are currently performing a longer-term follow-up of patients after treatment to evaluate any residual lesions and treatment efficacy. Therefore, more studies are needed to confirm the conclusions of our study and extrapolate these patients’ results in larger cohorts.

Conclusions

Our findings suggest that the impairments in cognitive functions for the HE patients were similar to those of AD patients except the remained naming ability. The MRI of HE showed leukoencephalopathy-like or limbic encephalitis-like type; the lesions did not affect the temporal cortex which plays a role in naming ability.

Author Contributions

Conceived and designed the experiments: JW JZ XW. Performed the experiments: JW JZ LX YS. Analyzed the data: JW QG. Contributed reagents/materials/analysis tools: LX YS. Wrote the paper: JW.

References

1. Schieß N, Pardo CA (2008) Hashimoto’s encephalopathy. Annals of the New York Academy of Sciences 1143: 254–265.
2. Mijajlovic M, Mirkovic M, Dackovic J, Živčev-Trakjovic J, Sternić N (2010) Clinical manifestations, diagnostic criteria and therapy of hashimoto’s encephalopathy: Report of two cases. Journal of the Neurological Sciences 289: 194–196.
3. Mocellin R, Walterfang M, Velakoulis D (2007) Hashimoto's encephalopathy : Epidemiology, pathogenesis and management. Clin Drugs 21: 799–811.
4. de Holanda NC, de Lima DD, Cavalcanti TB, Luena CS, Bandeira F (2011) Hashimoto’s encephalopathy: Systematic review of the literature and an additional case. J Neuropsychiatry Clin Neurosci 23: 384–390.
5. Tamagno G, Federspil G, Murialdo G (2006) Clinical and diagnostic aspects of encephalopathy associated with autoimmune thyroid disease (or hashimoto’s encephalopathy). Intern Emerg Med 1: 15–23.
6. Brooks BL, Barlow KM (2011) A methodology for assessing treatment response in hashimoto’s encephalopathy: A case study demonstrating repeated computerized neuropsychological testing. J Child Neurol 26: 786–791.
7. Shaw PJ, Walk TJ, Newman PK, Cleland PG, Cartledge NEF (1991) Hashimoto encephalopathy - a steroid-responsive disorder associated with high antithyroid antibody-titers - report of 5 cases. Neurology 41: 228–233.
8. Windblad B, Palmer K, Kivipelto M (2004) Mild cognitive impairment–beyond controversies, towards a consensus: Report of the international working group on mild cognitive impairment. Journal of Internal Medicine 256: 240–246.
9. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington: American Psychiatric Association Press.
10. Brain L, Jellinek EH, Ball K (1966) Hashimotos disease and encephalopathy. Lancet 2: 512–514.
11. Chang T, Riffsy MT, Gunaratne PS (2010) Hashimoto encephalopathy: Clinical and mri improvement following high-dose corticosteroid therapy. Neurologist 16: 394–396.
12. Guo Q, Sun Y, Yu P, Hong Z, Lv C (2007) Norm of auditory verbal learning test on chinese elderly patients with mild cognitive impairment and mild Alzheimer dementia. Chinese Journal of Clinical Psychology 15: 132–135.